Comparison of the prophylactic effect of silymarin and deferoxamine on iron overload-induced hepatotoxicity in rat

Journal of Medical Toxicology

Volumn 6, Issue 1, 2010, Pages 22-26

  Najafzadeh, Hossein ^a   Jalali, Mohammad Razi ^a   Morovvati, Hassan ^a   Taravati, Farnaz ^a  

^a SHAHID CHAMRAN UNIVERSITY OF AHVAZ   (Iran)

Author keywords

Deferoxamine; Hepatotoxicity; Iron overload; Rats; Silymarin

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; DEFEROXAMINE MESYLATE; IRON; IRON DEXTRAN; SILYMARIN;

ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BLOOD SAMPLING; CONTROLLED STUDY; DRUG EFFICACY; IRON BLOOD LEVEL; IRON OVERLOAD; LABORATORY TEST; LIVER INJURY; LIVER LEVEL; LIVER NECROSIS; LIVER PARENCHYMA; LIVER PROTECTION; LIVER TOXICITY; MALE; MICROSCOPY; NONHUMAN; RAT; TREATMENT DURATION;

ADMINISTRATION, ORAL; ALANINE TRANSAMINASE; ANIMALS; ASPARTATE AMINOTRANSFERASES; CYTOPROTECTION; DEFEROXAMINE; DISEASE MODELS, ANIMAL; DRUG-INDUCED LIVER INJURY; INJECTIONS, INTRAPERITONEAL; IRON; IRON OVERLOAD; IRON-DEXTRAN COMPLEX; LIVER; MALE; NECROSIS; RATS; RATS, WISTAR; SIDEROPHORES; SILYMARIN;

EID: 77951939187     PISSN: 15569039     EISSN: 19376995     Source Type: Journal    
DOI: 10.1007/s13181-010-0030-9     Document Type: Article

References (39)

1. Abu Ghadeer AR, Ali SE, Osman SA, Abu Bedair FA, Abbady MM, El-Kady MR (2001) Antagonistic role of silymarin against cardiotoxicity and impaired antioxidant induced by adriamycin and/or radiation exposure in albino rats. Pakistan J Biol Sci 4:604-607
2. Ahmed B, Khan SA, Alam T (2003) Synthesis and antihepatotoxic activity of some heterocyclic compounds containing the 1, 4-dioxane ring system. Pharmazie 58:173-176
3. Arezzini B, Lunghi B, Lungarella G, Gardi C (2003) Iron overload enhances the development of experimental liver cirrhosis in mice. Int J Biochem Cell Biol 35:486-495
4. Bacon BR, Britton RS (1990) The pathology of hepatic iron overload: a free radical-mediated process? Hepatol 11:127-137
5. Bhattacharya A, Ramanathan M, Ghosal S, Bhattacharya SK (2000) Effect of withania samra glycoeithanolides on iron-induced hepatotoxicity in rats. Phytother Res 14:568-570
6. Borsari M, Gabbi C, Ghelfi F, Grandi R, Saladini M, Severi S, Borella F (2001) Silybin, a new iron-chelating agent. J Inorg Biochem 85:123-129
7. Chon SK, Kim NS (2005) Evaluation of silymarin in the treatment on asymptomatic Giardia infections in dogs. Parasitol Res 97:445-451
8. Crocenzi FA, Sanchez Pozzi EJ, Pellegrino JM, Rodriguez Garay EA, Mottino AD, Roma MG (2003) Preventive effect of silymarin against taurolithocholate-induced cholestasis in the rat. Biochem Pharmacol 66:355-364
9. Dong JJ, Bauer M (2001) Antifibrotic effect of silymarin in rat secondary biliary fibrosis is mediated by down regulation of procollagen1 (I) and TIMP-1. J Hepatol 35:392-398
10. Emerit J, Beaumont C, Trivin F (2001) Iron metabolism, free radicals and oxidative injury. Biomed Pharmacother 55:333-339
11. Farinati F, Cardin R, De Maria N, Della Libera G, Marafin C, Lecis E, Burra P, Floreani A, Cecchetto A, Naccarato R (1995) Iron storage, lipid peroxidation and glutathione turnover in chronic anti-HCV positive hepatitis. J Hepatol 22:449-456
12. Flora K, Hahn M, Rosen H, Benner K (1998) Milk thistle (Silybum marianum) for the therapy of liver disease. Am J Gastroenterol 93(2):139-43
13. George DK, Goldwurm S, MacDonald GA, Cowley LL, Walker NI, Ward PJ, Jazwinska EC, Powell LW (1998) Increased hepatic iron concentration in nonalcoholic steatohepatitis is associated with increased fibrosis. Gastroenterol 114:311-318
14. George DK, Ramm GA, Powell LW, Fletcher LM, Walker NI, Cowley LL, Crawford DH (1998) Evidence for altered hepatic matrix degradation in genetic haemochromatosis. Gut 42:715-720
15. Hakova H, Misurova E, Kropacova R (1996) The effect of silymarin on the concentration and total content of nucleic acids in tissues of continuously irradiated rats. Vet Med (Praha) 41:113-119
16. Houglum K, Filip M, Josephl W, Chojkier M (1990) Malondialehyde and 4-hydroxyno nenal protein adducts in plasma and liver of rats with iron overloads. J Clinic Investig Inc 86:1991-1998
17. Jensen PD, Jensen FT, Christensen T, Nielsen JL, Ellegaard J (2003) Relationship between hepatocellular injury and transfusional iron overload prior to and during iron chelation with desferrioxamine: a study in adult patients with acquired anemias. Blood 101(1):91-96
18. Kadikoylu G, Bolaman Z, Demir S, Balkaya M, Akalin N, Enli Y (2004) The effects of desferrioxamine on cisplatininduced lipid peroxidation and the activities of antioxidant enzymes in rat kidneys. Hum Exp Toxicol 23:29-34
19. Kang JS, Jeon YJ, Park SK, Yang KH, Kim HM (2004) Protection against lipopolysaccharide-induced sepsis and inhibition of interleukin-1 beta and prostaglandin E2 synthesis by silymarin. Biochem Pharmacol 67:175-181
20. Kontoghiorghes GJ, Pattichi K, Hadjigavriel M, Kolnagou A (2000) Transfusional iron overload and chelation therapy with deferoxamine and deferiprone (L1). Transfus Sci 23:211-223
21. Laekeman G, De Coster S, De Meyer K, Leuven KU (2003) St. Mary's Thistle: an overview. J Pharm Belg 58:28-31
22. Ludwig J, Hashimoto E, Porayko MK, Moyer TP, Baldus WP (1997) Hemosiderosis in cirrhosis: a study of 447 native livers. Gastroenterol 112:882-888
23. Mayers M, Brent G, Prendergast F, Holman R, Kuntz S, Larusso N (1991) Alterations in the structure, physiochemical properties, and pH of hepatocyte lysosomes in experimental iron overload. J Clin Invest Inc 88:1207-1215
24. Medina J, Moreno-Otero R (2005) Pathophysiological basis for antioxidant therapy in chronic liver disease. Drugs 65:2445-2461
25. Mereish KA, Bunner DL, Regland DR, Creasia DA (1991) Protection against microcystin-L. R. induced hepatotoxicity by silymarin: biochemistry, histopathology and lethality. Pharmacol Res 8:257-277
26. Mira L, Silva M, Manso CF (1994) Scavenging of reactive oxygen species by silibin dihemisuccinate. Biochem Pharmacol 48:753-759
27. Naveau S (2001) Acute alcoholic hepatitis treatments. Press Med 30:1024-1030
28. Oliveira C, Lopasso FP, Laurindo F, Leitao R, Laundanna AA (2001) Protection against liver ischemia-reperfusion injury in rats by silymarin or verapamil. Transplant Proc 33:3010-3014
29. Peretz G, Link G, Pappo O, Bruck R, Ackerman Z (2006) Effect of hepatic iron concentration reduction on hepatic fibrosis and damage in rats with cholestatic liver disease. World J Gastroenterol 12(2):240-245
30. Pietrangelo A (1996) Metals, oxidative stress, and hepatic fibrogenesis. Semin Liver Dis 16:13-30
31. Poli G, Parola M (1997) Oxidative damage and fibrogenesis. Free Radic Biol Med 22:287-305
32. Ramadan L, Roushdy HM, Abu Senna GM, Amin NE, El-Deshw OA (2002) Radioprotectve effect of silymarin against radiation induced hepatotoxicity. Pharmacol Res 45:447-452
33. Saller R, Meier R, Brignoli R (2001) The use of silymarin in the treatment of liver disease. Drugs 61(4):2034-2061
34. Soto C, Recoba R, Barron H, Alvarez C, Favari L (2003) Silymarin increases antioxidant enzymes in alloxan-induced diabetes in rat pancreas. Comp Biochem Physiol C Toxicol Pharmacol 136:205-212
35. Valenzuela A, Monica A, Soledad V, Ricardo G (1989) Selectivity of silymarin on the increase of the glutathione content in different tissues of the rats. Planta Med 55:420-422
36. Varzi NH, Esmailzadeh S, Morovvati H, Avizeh R, Shahriari A, Givi EM (2007) Effect of silymarin and vitamin E on gentamicin-induced nephrotoxicity in dogs. J Vet Pharmacol Ther 30:477-481
37. Vladimir K, Daniela W (2005) Silybin and silymarin-new effects and applications. Biomedical Papers 149:29-41
38. Whittaker P, Hines FA, Robl MG, Dunkel VC (1996) Histopathological evaluation of liver, pancreas, spleen, and heart from iron-overloaded Sprague-Dawley rats. Toxicol Pathol 24(5):558-563
39. Zhao Y, Li H, Gao Z, Xu H (2005) Effects of dietary baicalin supplementation on iron overload-induced mouse liver oxidative injury. Europ J Pharmacol 509(2-3):195-200